WO2011009020A3 - Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers - Google Patents

Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers Download PDF

Info

Publication number
WO2011009020A3
WO2011009020A3 PCT/US2010/042218 US2010042218W WO2011009020A3 WO 2011009020 A3 WO2011009020 A3 WO 2011009020A3 US 2010042218 W US2010042218 W US 2010042218W WO 2011009020 A3 WO2011009020 A3 WO 2011009020A3
Authority
WO
WIPO (PCT)
Prior art keywords
phototherapy
compounds
treatment
cancers
compositions
Prior art date
Application number
PCT/US2010/042218
Other languages
French (fr)
Other versions
WO2011009020A2 (en
Inventor
Gary L. Cantrell
David W. Berberich
Raghavan Rajagopalan
Amolkumar Karwa
Original Assignee
Mallinckrodt Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc. filed Critical Mallinckrodt Inc.
Priority to US13/383,243 priority Critical patent/US8829020B2/en
Publication of WO2011009020A2 publication Critical patent/WO2011009020A2/en
Publication of WO2011009020A3 publication Critical patent/WO2011009020A3/en
Priority to US14/316,443 priority patent/US9527858B2/en
Priority to US14/316,415 priority patent/US9518062B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans

Abstract

The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.
PCT/US2010/042218 2009-07-16 2010-07-16 Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers WO2011009020A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/383,243 US8829020B2 (en) 2009-07-16 2010-07-16 Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US14/316,443 US9527858B2 (en) 2009-07-16 2014-06-26 Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US14/316,415 US9518062B2 (en) 2009-07-16 2014-06-26 Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US22603209P 2009-07-16 2009-07-16
US22601509P 2009-07-16 2009-07-16
US61/226,032 2009-07-16
US61/226,015 2009-07-16
US23835809P 2009-08-31 2009-08-31
US61/238,358 2009-08-31
US28687709P 2009-12-16 2009-12-16
US61/286,877 2009-12-16

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US13/383,243 A-371-Of-International US8829020B2 (en) 2009-07-16 2010-07-16 Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US14/316,415 Continuation US9518062B2 (en) 2009-07-16 2014-06-26 Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US14/316,443 Continuation US9527858B2 (en) 2009-07-16 2014-06-26 Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers

Publications (2)

Publication Number Publication Date
WO2011009020A2 WO2011009020A2 (en) 2011-01-20
WO2011009020A3 true WO2011009020A3 (en) 2011-03-10

Family

ID=42797333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/042218 WO2011009020A2 (en) 2009-07-16 2010-07-16 Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers

Country Status (2)

Country Link
US (3) US8829020B2 (en)
WO (1) WO2011009020A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518062B2 (en) 2009-07-16 2016-12-13 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2379066E (en) * 2008-09-16 2014-07-04 Imuneks Farma Ilaç Sanayi Ve Ticaret A S Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
US20110015219A1 (en) * 2009-07-16 2011-01-20 Mallinckrodt Inc. (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof
KR20130030261A (en) 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. Manufacturing of active-free granules and tablets comprising the same
PE20130657A1 (en) 2010-05-10 2013-06-15 Euro Celtique Sa PHARMACEUTICAL COMPOSITIONS INCLUDING HYDROMORPHONE AND NALOXONE
EP2568965A1 (en) 2010-05-10 2013-03-20 Euro-Celtique S.A. Combination of active loaded granules with additional actives
MX2013008749A (en) * 2011-01-31 2013-10-17 Toray Industries Therapeutic or prophylactic agent for cachexia.
FR2975600B1 (en) * 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris AGENTS FOR THE TREATMENT OF TUMORS
WO2013044166A1 (en) * 2011-09-23 2013-03-28 Schwartz Alan N Non-invasive and minimally invasive and tightly targeted minimally invasive therapy methods and devices for parathyroid treatment
WO2013119954A1 (en) * 2012-02-08 2013-08-15 Walter Reed Army Institute Of Research Department Of The Army Induction of highly specific antibodies to a hapten but not to a carrier peptide by immunization
MX366726B (en) * 2012-02-27 2019-07-22 Bayer New Zealand Ltd Controlled release compositions and their methods of use.
KR102194174B1 (en) 2013-11-13 2020-12-23 유로-셀티큐 에스.에이. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
GB201520390D0 (en) * 2015-11-19 2016-01-06 Euro Celtique Sa Composition
CN105461727A (en) * 2015-12-01 2016-04-06 吕涛 Refining method of nalfurafine
US11214544B2 (en) * 2017-04-14 2022-01-04 Kempharm, Inc. Dextrorphan prodrugs and processes for making and using them
US11234975B2 (en) * 2017-04-14 2022-02-01 Kempharm, Inc. Levorphanol prodrugs and processes for making and using them
US10357567B1 (en) 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy
CN110143921A (en) * 2019-06-30 2019-08-20 上海葆隆生物科技有限公司 A kind of preparation method of dextromethorphan hydrobromide N-oxide impurity

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070031A1 (en) * 2000-03-23 2001-09-27 Zagan Ian S Opioid growth factor modulates angiogenesis
US20030171320A1 (en) * 2001-11-09 2003-09-11 Guyer David R. Methods for treating ocular neovascular diseases
US20050107415A1 (en) * 2002-05-17 2005-05-19 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
WO2006016143A1 (en) * 2004-08-09 2006-02-16 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
WO2006096626A2 (en) * 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2007121447A2 (en) * 2006-04-17 2007-10-25 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2008064351A2 (en) * 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2009067275A1 (en) * 2007-11-21 2009-05-28 Progenics Pharmaceuticals, Inc N-oxides of 4,5-epoxy-morphinanium analogs
EP2149372A1 (en) * 2008-07-31 2010-02-03 Universität Ulm Use of opioids or opioid mimetics for the treatment of resistant cancer patients
WO2010096788A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-morphinanium quaternary salts and processes for their production
WO2010096790A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-morphinananium n-oxides and processes for their production

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB624391A (en) 1947-02-20 1949-06-07 Hoffmann La Roche A process for the manufacture of piperido-phenanthrene derivatives and salts thereof
GB797954A (en) 1955-06-29 1958-07-09 Crookes Lab Ltd Injectable substances comprising salts of therapeutic bases
DE1119284B (en) 1959-09-02 1961-12-14 Boehringer Sohn Ingelheim Process for the preparation of antagonistic quaternary salts of normorphine and their acylated derivatives with antagonistic effects against morphine and analgesic
US4521601A (en) 1981-05-20 1985-06-04 The United States Of America As Represented By The Department Of Health & Human Services Practical total synthesis unnatural enantiomers of opium-derived morphinans
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4990617A (en) 1985-12-02 1991-02-05 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans and derivatives
US4722928A (en) 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
US5668285A (en) 1986-10-31 1997-09-16 The United States Of America As Represented By The Department Of Health And Human Services Total synthesis of northebaine, normophine, noroxymorphone enantiomers and derivatives via N-Nor intermediates
US4883790A (en) 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
FR2623810B2 (en) 1987-02-17 1992-01-24 Sanofi Sa ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4968715A (en) 1988-07-06 1990-11-06 Health Research, Inc. Use of purified hematoporphyrin trimers in photodynamic therapy
US5190966A (en) 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US5093349A (en) 1988-07-20 1992-03-03 Health Research Inc. Photosensitizing agents
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5198460A (en) 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
US5173504A (en) 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5171741A (en) 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5079262A (en) 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
PT95069B (en) 1989-08-24 1997-10-31 Searle & Co PROCESS FOR THE PREPARATION OF (+) - ISOMERS OF DERIVATIVES OF ENDOETANO / ENDOETANOEPOXIMOFINANO, UTEIS AS ANTI-TUSTIC AGENTS
US5166197A (en) 1990-07-17 1992-11-24 Kenney Malcolm E Phthalocyanine photosensitizers for photodynamic therapy
JPH06500554A (en) 1990-08-23 1994-01-20 ザ・チルドレンズ・メディカル・センター・コーポレイション Treatment of AIDS-related dementia, myelopathy, peripheral neuropathy, and vision loss
CH683005A5 (en) 1991-10-30 1993-12-31 Aldo Massarotti Prepn. of N-oxide(s) of opioid analgesics and antagonists - for treating opiate drug addiction without prior art side effects, e.g. 6-di:methylamino 4,4-di:phenyl 3-heptanone N-oxide
ES2121988T3 (en) 1992-01-23 1998-12-16 Toray Industries DERIVATIVE OF MORFINANO AND MEDICINAL USE.
US5244914A (en) 1992-04-27 1993-09-14 American Cyanamid Company Stable porfimer sodium compositions and methods for their manufacture
US5352680A (en) 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5405957A (en) 1992-10-30 1995-04-11 The University Of British Columbia Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
DE69413933T2 (en) 1993-06-30 1999-04-08 Toray Industries ANTITUSSIVA
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US5919826A (en) 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
EP0897726B1 (en) 1996-11-25 2007-04-11 Toray Industries, Inc. Antipruritic agent
ES2217533T3 (en) 1997-01-16 2004-11-01 Toray Industries, Inc. INDOLOMORFINAN DERIVATIVES AND PREVENTIVE MEDICINES FOR BRAIN DISORDERS.
AU727080B2 (en) 1997-06-30 2000-11-30 Allergan, Inc. Calcium blockers to treat proliferative vitreoretinopathy
CA2319433C (en) 1998-02-09 2008-04-22 Bracco Research S.A. Targeted delivery of biologically active media
US6287607B2 (en) 1999-07-19 2001-09-11 Mission Pharmacal Company Potassium calcium citrate compositions and methods therefor
WO2001014382A1 (en) 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan
US20030026945A1 (en) 1999-11-09 2003-02-06 Vincent P. Lasko Nonwoven material comprising an adhesive and apertures
JP2001163784A (en) 1999-12-06 2001-06-19 Toray Ind Inc Antipruritic for cornea or conjunctiva
US7235685B2 (en) 2001-07-03 2007-06-26 Mallinckrodt, Inc. Aromatic sulfenates for type I phototherapy
US20030017164A1 (en) 2001-07-03 2003-01-23 Mallinckrodt Inc. Dye-azide compounds for dual phototherapy
US20020169107A1 (en) 2001-01-19 2002-11-14 Mallinckrodt Inc. Novel aromatic azides for type I phototherapy
US7198778B2 (en) 2000-01-18 2007-04-03 Mallinckrodt Inc. Tumor-targeted optical contrast agents
US6180086B1 (en) 2000-01-18 2001-01-30 Mallinckrodt Inc. Hydrophilic cyanine dyes
US7351807B2 (en) 2000-01-18 2008-04-01 Mallinckrodt Inc. Cyanine-sulfenates for dual phototherapy
US7230088B2 (en) 2001-07-03 2007-06-12 Mallinckrodt, Inc. Compounds for dual photodiagnosis and therapy
US7790144B2 (en) 2000-01-18 2010-09-07 Mallinckrodt Inc. Receptor-avid exogenous optical contrast and therapeutic agents
WO2001074819A1 (en) 2000-04-03 2001-10-11 Toray Industries, Inc. Analgesics containing morphinan n-oxide derivatives as the active ingredient
JP4024992B2 (en) 2000-04-27 2007-12-19 オリバー ヤオ−プ フ Polynalbuphine derivative and method for producing the same
CA2408323C (en) 2000-05-08 2012-06-12 The University Of British Columbia Drug delivery systems for photodynamic therapy
US20020026945A1 (en) 2000-07-24 2002-03-07 Gomer Charles J. Enhancement of photodynamic therapy by anti-angiogenic treatment
AUPQ968300A0 (en) 2000-08-25 2000-09-21 Glaxo Wellcome Australia Ltd Chemical methods
WO2002062386A2 (en) 2001-02-06 2002-08-15 Qlt Inc. Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration
US6747151B2 (en) 2001-05-04 2004-06-08 Mallinckrodt, Inc. Azo compounds for type I phototherapy
US6485704B1 (en) 2001-05-04 2002-11-26 Mallinckrodt Inc. Azo compound for type I pototherapy
WO2003007944A1 (en) 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US7087212B2 (en) 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
US6761878B2 (en) 2001-10-17 2004-07-13 Mallinckrodt, Inc. Pathological tissue detection and treatment employing targeted benzoindole optical agents
US20030105299A1 (en) 2001-10-17 2003-06-05 Mallinckrodt Inc. Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications
US20030105300A1 (en) 2001-10-17 2003-06-05 Mallinckrodt Inc. Tumor targeted photodiagnostic-phototherapeutic agents
EP2987788A1 (en) 2002-05-17 2016-02-24 Taiwanj Pharmaceuticals Co., Ltd. Opioid and opioid-like compounds and uses thereof
US7501433B2 (en) 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
DE10229842A1 (en) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinane derivatives and their quaternary ammonium salts substituted in position 14, production process and use
AU2003290630B2 (en) 2002-11-08 2009-01-29 SpecGx LLC Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
ATE454169T1 (en) 2003-03-13 2010-01-15 Controlled Chemicals Inc OXYCODONE CONJUGATES WITH LOWER ABUSE POTENTIAL AND EXTENDED DURATION
US20050004155A1 (en) 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
RU2005134364A (en) 2003-04-08 2006-06-10 Проджиникс Фармасьютикалз, Инк. (Us) COMBINED TREATMENT FOR CONSTIPATION
CA2539659C (en) 2003-09-22 2013-03-26 Johnson Matthey Public Limited Company Process for the synthesis of morphinane compounds and intermediates thereof
US20050245557A1 (en) 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
AU2003303744A1 (en) 2003-10-31 2005-06-17 Elan Pharma International Ltd. Novel nimesulide compositions
WO2006073419A2 (en) 2004-04-01 2006-07-13 Gang Zheng Lipoprotein nanoplatforms
EP1595541A1 (en) 2004-05-12 2005-11-16 Alcasynn Pharmaceuticals Gmbh Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
AU2005277361A1 (en) 2004-08-17 2006-03-02 Mallinckrodt Inc. Process for the production of levorphanol and related compounds
AU2005292184A1 (en) 2004-10-01 2006-04-13 The Research Foundation Of State University Of New York Morphine and morphine precursors
AU2005305210B2 (en) 2004-11-04 2012-01-19 SpecGx LLC Opiate intermediates and methods of synthesis
WO2006098855A2 (en) 2005-03-10 2006-09-21 Mallinckrodt Inc. Processes for preparing morphinans and intermediates thereof
HUE029202T2 (en) 2005-04-06 2017-02-28 Toray Industries Crystals of morphinan derivative and process for producing the same
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
US8114843B2 (en) 2005-11-18 2012-02-14 The Regents Of The University Of California Photoreactive regulator of protein function and methods of use thereof
CN100502867C (en) * 2005-12-16 2009-06-24 杏林科技有限公司 Preparation of sinomenine as antineoplastic medicament
WO2007072503A2 (en) 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
US20070185145A1 (en) 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
JP2009528373A (en) 2006-03-02 2009-08-06 マリンクロッド・インコーポレイテッド Thiadiazole compounds and their use for phototherapy
FR2904225B1 (en) 2006-07-28 2010-08-13 Bouchara Recordati PHARMACEUTICAL COMPOSITIONS OF ACTIVE SUBSTANCES DIFFICULTY OF THE ROUTE OF ADMINISTRATION TO WHICH THEY ARE INTENDED
NZ575620A (en) 2006-09-20 2010-11-26 Mallinckrodt Inc Preparation of substituted morphinan-6-ones and salts and intermediates thereof
FR2906252B1 (en) 2006-09-21 2008-11-28 Sanofi Aventis Sa PROCESS FOR THE PREPARATION OF NALTREXONE N-AKLYL HALIDES
WO2008060764A2 (en) 2006-10-05 2008-05-22 Drugtech Corporation Topical therapies for oral mucositis and other conditions
BRPI0719587A2 (en) 2006-11-22 2013-12-17 Progenics Pharm Inc (S) - 7,8-SATURATED-4,5-EPOXY-MORFINAN ANALOG STEREO ISOMERS
US20080234306A1 (en) 2006-11-22 2008-09-25 Progenics Pharmaceuticals, Inc. N-Oxides of 4,5-Epoxy-Morphinanium Analogs
WO2008064150A1 (en) 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. Processes for synthesizing quaternary 4,5-epoxy-morphinan analogs and isolating their n-stereoisomers
KR100863692B1 (en) 2006-12-08 2008-10-15 울산대학교 산학협력단 7-hydroxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline derivatives having effects of preventing and treating degenerative and inflammatory diseases
EP2161253A3 (en) 2006-12-11 2010-05-26 Mallinckrodt Inc. Process for the preparation of 3,4-dihydroisoquinolines in the synthesis of morphinans
WO2008073381A2 (en) 2006-12-11 2008-06-19 University Of Kentucky Research Foundation Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
CA2672745C (en) 2006-12-12 2016-03-22 Peter X. Wang A process for the preparation of hexahydroisoquinolines from 1,2,3,4-tetrahydroisoquinolines
CN101626786A (en) 2007-03-01 2010-01-13 马林克罗特公司 Integrated photoactive peptides and uses thereof
WO2008108944A2 (en) 2007-03-01 2008-09-12 Mallinckrodt Inc. Integrated photoactive small molecules and uses thereof
CA2679807A1 (en) 2007-03-02 2008-09-12 Schering Corporation Piperidine derivatives and methods of use thereof
KR20090127902A (en) 2007-03-02 2009-12-14 쉐링 코포레이션 Benzimidazole derivatives and methods of use thereof
EP2137189B1 (en) 2007-03-06 2015-05-06 Mallinckrodt LLC Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
CN102964302B (en) 2007-05-01 2015-10-21 康塞特医药品公司 Morphinan compounds
EP2180000B1 (en) 2007-05-04 2013-03-27 Mallinckrodt LLC Improved process for the preparation of 6-alpha-hydroxy-n-alkylated opiates
CN101066948B (en) 2007-05-30 2012-01-04 广东工业大学 Catalytic hydrogenation and reduction process of coculine for preparing hydrogenated coculine
WO2009009292A2 (en) 2007-07-11 2009-01-15 Mallinckrodt Inc. Crystalline forms of naltrexone methobromide
NZ582668A (en) 2007-07-17 2012-02-24 Mallinckrodt Llc Preparation of n-alkylated opiates by reductive amination
WO2009059048A2 (en) 2007-10-30 2009-05-07 The Regents Of The University Of Colorado (+)-opioids and methods of use
JP2011503067A (en) 2007-11-07 2011-01-27 マリンクロッド・インコーポレイテッド Crosslinked and functionalized nanostructures with photonic shell cores for biological applications
FR2923484B1 (en) 2007-11-09 2012-11-09 Sanofi Aventis PROCESS FOR THE PREPARATION OF MORPHINIC COMPOUNDS
AU2008338969B2 (en) 2007-12-17 2013-08-01 SpecGx LLC Process and compounds for the production of (+) opiates
NZ586187A (en) 2007-12-17 2013-07-26 Mallinckrodt Llc Processes for the synthesis of sinomenine derivatives and their intermediate
CN101896489A (en) 2007-12-17 2010-11-24 马林克罗特公司 Process for the preparation of buprenorphine and derivatives of buprenorphine
CN101896487A (en) 2007-12-17 2010-11-24 马林克罗特公司 N-demethylation of N-methyl morphinans
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CN101265266B (en) 2008-04-23 2011-12-14 南京大学 Sinomenine derivative, preparation method and application thereof
CN102131509B (en) 2008-05-22 2015-01-07 特拉维夫大学拉莫特有限公司 Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
WO2009155259A1 (en) 2008-06-17 2009-12-23 Mallinckrodt Inc. Processes for the preparation of 6- beta-hydroxy morphinan compounds
WO2009152577A1 (en) 2008-06-20 2009-12-23 Tpi Enterprises Pty Ltd Process for the synthesis of n-demethylated morphinane compounds
WO2010002576A1 (en) 2008-07-01 2010-01-07 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
UA105182C2 (en) 2008-07-03 2014-04-25 Ньюрексон, Інк. Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
CN102197037B (en) 2008-09-19 2015-02-18 康塞特医药品公司 Morphinan compounds
WO2010039209A2 (en) 2008-09-30 2010-04-08 Mallinckrodt Inc. Processes for the synthesis of tertiary amines
WO2010060018A1 (en) 2008-11-24 2010-05-27 Mallinckrodt Inc. Azo and diaza derivatives and uses thereof in phototherapy
KR20100090155A (en) 2009-02-05 2010-08-13 엘지전자 주식회사 Mobile terminal and presence information processing method thereof
JP2012518652A (en) 2009-02-23 2012-08-16 マリンクロッド インコーポレイテッド (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
WO2010132554A2 (en) 2009-05-12 2010-11-18 Mallinckrodt Inc. Diaza heterocyclic compounds for phototherapy
WO2010132525A1 (en) 2009-05-12 2010-11-18 Mallinckrodt Inc. Compounds containing acyclic n-o bonds for phototherapy
WO2010132515A1 (en) 2009-05-12 2010-11-18 Mallinckrodt Inc. Compounds containing acyclic n-n bonds for phototherapy
WO2010132547A2 (en) 2009-05-12 2010-11-18 Mallinckrodt Inc. Oxaza heterocyclic compounds for phototherapy
US8519133B2 (en) 2009-06-11 2013-08-27 Mallinckrodt Llc Preparation of 6-alpha-amino N-substituted morphinans by catalytic hydrogen transfer
US20110015219A1 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
WO2011060113A1 (en) 2009-11-11 2011-05-19 Mallinckrodt Inc. Sulfenamide compounds for phototherapy
WO2011084571A2 (en) 2009-12-16 2011-07-14 Mallinckrodt Inc. Azide derivatives for phototherapy
US8538577B2 (en) 2010-03-05 2013-09-17 Crown Equipment Limited Method and apparatus for sensing object load engagement, transportation and disengagement by automated vehicles
US20110288033A1 (en) 2010-05-19 2011-11-24 Mallinckrodt Inc. Disulfide Compounds for Phototherapy
ES2728701T3 (en) 2010-07-16 2019-10-28 Mallinckrodt Llc (+) - Morphinans as antagonists of the Toll-type receptor 9 and therapeutic applications thereof

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070031A1 (en) * 2000-03-23 2001-09-27 Zagan Ian S Opioid growth factor modulates angiogenesis
US20030171320A1 (en) * 2001-11-09 2003-09-11 Guyer David R. Methods for treating ocular neovascular diseases
US20050107415A1 (en) * 2002-05-17 2005-05-19 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
WO2006016143A1 (en) * 2004-08-09 2006-02-16 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
WO2006096626A2 (en) * 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2007121447A2 (en) * 2006-04-17 2007-10-25 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2008064351A2 (en) * 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2009067275A1 (en) * 2007-11-21 2009-05-28 Progenics Pharmaceuticals, Inc N-oxides of 4,5-epoxy-morphinanium analogs
EP2149372A1 (en) * 2008-07-31 2010-02-03 Universität Ulm Use of opioids or opioid mimetics for the treatment of resistant cancer patients
WO2010096788A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-morphinanium quaternary salts and processes for their production
WO2010096790A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-morphinananium n-oxides and processes for their production

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHANG C -J ET AL: "The capabilities of benzoporphyrin: In vivo study of canine malignant melanomas with photodynamic therapy", FORMOSAN JOURNAL OF SURGERY 200207 TW, vol. 35, no. 4, July 2002 (2002-07-01), pages 166 - 172, XP009139725, ISSN: 1011-6788 *
FERRARIO A ET AL: "ANTIANGIOGENIC TREATMENT ENHANCES PHOTODYNAMIC THERAPY RESPONSIVENESS IN A MOUSE MAMMARY CARCINOMA", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 60, 1 August 2000 (2000-08-01), pages 4066 - 4069, XP000996666, ISSN: 0008-5472 *
LI X J ET AL: "Effect of sinomenine on gene expression of the IL-1beta-activated human synovial sarcoma", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB LNKD- DOI:10.1016/J.LFS.2006.02.014, vol. 79, no. 7, 10 July 2006 (2006-07-10), pages 665 - 673, XP025191511, ISSN: 0024-3205, [retrieved on 20060710] *
PARK H S ET AL: "A case of prurigo nodularis treated with narrow-band UVB and naltrexone", KOREAN JOURNAL OF DERMATOLOGY 200508 KR, vol. 43, no. 8, August 2005 (2005-08-01), pages 1113 - 1115, XP001525293, ISSN: 0494-4739 *
SHE HAICHENG ET AL: "Photoreceptor Protection after Photodynamic Therapy Using Dexamethasone in a Rat Model of Choroidal Neovascularization", IOVS, vol. 49, no. 11, November 2008 (2008-11-01), pages 5008 - 5014, XP002604043, ISSN: 0146-0404 *
SHEN J ET AL: "Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB LNKD- DOI:10.1038/SJ.GT.3302641, vol. 13, no. 3, 29 September 2005 (2005-09-29), pages 225 - 234, XP002441146, ISSN: 0969-7128 *
SINGLETON PATRICK A ET AL: "Attenuation of vascular permeability by methylnaltrexone - Role of mOP-R and S1P3 transactivation", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 37, no. 2, August 2007 (2007-08-01), pages 222 - 231, XP002603995, ISSN: 1044-1549 *
TANABE S ET AL: "Fluorescence detection of a new photosensitizer, PAD-S31, in tumour tissues and its use as a photodynamic treatment for skin tumours in dogs and a cat: A preliminary report", VETERINARY JOURNAL 200405 GB LNKD- DOI:10.1016/J.TVJL.2003.07.001, vol. 167, no. 3, May 2004 (2004-05-01), pages 286 - 293, XP002603996, ISSN: 1090-0233 *
ZULUAGA MARIA-FERNANDA ET AL: "Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration", IOVS, vol. 48, no. 4, April 2007 (2007-04-01), pages 1767 - 1772, XP002604044, ISSN: 0146-0404 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518062B2 (en) 2009-07-16 2016-12-13 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US9527858B2 (en) 2009-07-16 2016-12-27 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers

Also Published As

Publication number Publication date
US20120129879A1 (en) 2012-05-24
US9518062B2 (en) 2016-12-13
US8829020B2 (en) 2014-09-09
WO2011009020A2 (en) 2011-01-20
US20140370005A1 (en) 2014-12-18
US9527858B2 (en) 2016-12-27
US20140370006A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
WO2011009020A3 (en) Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
MX2020012868A (en) Methods and compositions for sleep disorders and other disorders.
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
IL242268A0 (en) Combinations and modes of administration of therapeutic agents and combination therapy
HK1157337A1 (en)
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
NZ598137A (en) Oxazine derivatives and their use in the treatment of neurological disorders
WO2005105213A3 (en) Indole and azaindole derivatives with antitumor action
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
UA99141C2 (en) Substituted indazole derivatives active as kinase inhibitors
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
HK1126119A1 (en) Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3- propanaediol derivative as active ingredient, and its use in manufacture of medicines for preventing or treating inflammatory bowel disease 2--13-
MX2011007589A (en) Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody.
BRPI0921097A2 (en) pyrazol-3 carboxamide derivative compound with 5-ht2b receptor antagonist activity, preventive or therapeutic agent, pharmaceutical composition and use of the compound or pharmaceutically acceptable salt thereof and method or prevention or treatment.
MX2017017138A (en) Targeted conjugates of ksp inhibitors.
MX2009004561A (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
WO2009068659A3 (en) Novel disease treatment by predicting drug association
MX358492B (en) Slow intraventricular delivery.
WO2014160216A3 (en) Dual targeting anticancer agents
AU2018256619A1 (en) Compounds for the treatment of obesity and methods of use thereof
MX2009011900A (en) Diabetic wound healing.
MX2013008175A (en) Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof.
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10734626

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 13383243

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10734626

Country of ref document: EP

Kind code of ref document: A2